Last reviewed · How we verify
NCT07080346
Upadacitinib for Refractory Behcet's Syndrome
Phase 2 trial testing Upadacitinib 15 MG in Behcet Syndrome in 27 participants. Completed in 8 July 2025.
20 December 2024
Quick facts
| Lead sponsor | Liu Tian |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 27 |
| Start date | 25 January 2024 |
| Primary completion | 20 December 2024 |
| Estimated completion | 8 July 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Upadacitinib 15 MG — full drug profile →
Conditions studied
- Behcet Syndrome — all drugs for Behcet Syndrome →
Sponsor
Liu Tian
Who can join
Adults 18 to 80, any sex, with Behcet Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Behçet's syndrome (BS) is a systemic autoimmune vasculitis that can affect multiple organs, including the skin, eyes, and vascular system. Refractory BS poses significant treatment challenges, necessitating novel therapeutic approaches. Upadacitinib, a selective JAK1 inhibitor within the JAK-STAT pathway, has shown promise in modulating immune responses. This study aims to evaluate the efficacy and safety of upadacitinib in patients with refractory BS.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Upadacitinib for refractory Behcet's syndrome: a multi-centre, single-arm trial.
Li J, Xia W, Ji H, Gong X, et al · · 2026 · PMID 41776676 · DOI 10.1186/s13075-026-03778-x
Verify or expand the search:
- PubMed search for NCT07080346
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Upadacitinib 15 MG
Trials testing the same drug.
- NCT06687551 — JAK Inhibitor Dose TAPering Strategy Study · Phase 4 · not yet recruiting
- NCT06454461 — Efficacy of Upadacitinib After NECS in Vitiligo · NA · recruiting
- NCT06379958 — Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects · Phase 1 · recruiting
- NCT06758947 — Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF · Phase 3 · completed
Other recruiting trials for Behcet Syndrome
Currently open trials in the same condition.
- NCT06780462 — Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep V · Phase 3 · recruiting
- NCT06730958 — Evaluation of Serum Follistatin-Like Protein 1 Levels in Behcet's Disease and Its Association With Disease Activity · recruiting
- NCT06729112 — Pan-immune-inflammation Value (PIN) in Behçet's Disease and Its Correlation With Disease Activity · recruiting
- NCT05200715 — AutoInflammatory Disease Alliance Registry (AIDA) · recruiting
Other Liu Tian trials
Trials by the same sponsor.
- NCT07500467 — Upadacitinib for Refractory Takayasu Arteritis · completed
- NCT06662721 — Baricitinib for Refractory Takayasu Arteritis · Phase 2 · completed
- NCT05339217 — Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07080346 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Liu Tian
- Last refreshed: 2 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07080346.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing